ESR1 and breast carcinoma: Since it degraded ERα while concomitantly inducing the anti-proliferative ERβ, it has been suggested that the anti-tumor properties of RO48-8071 are in part due to an off-target effect that increases the ratio of ERβ/ERα in breast cancer cells [33].